|5 mg||-||Unavailable in your region|
Product Pathways - MAPK Signaling
|9052S||5 mg||---||In Stock||---|
- Molecular Formula:
Directions For Use
Dasatinib is supplied as a lyophilized powder. For a 5 mM stock, reconstitute the 5 mg in 2.05 mL DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 50-500 nM for 2-6 hours. Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol and water with maximum solubility in water estimated to be about 10 μM.
Western blot analysis of extracts from LNCaP cells, untreated (-) or treated with dasatinib (100 nM, 2 hr; +), using Phospho-Src Family (Tyr416) Antibody #2101 (upper) and Src (36D10) Rabbit mAb #2109 (lower).
Dasatinib is a small molecule inhibitor of both the Src and Bcr-Abl tyrosine kinases, with IC50 values of 0.55 and 3.0 nM for the isolated kinases, respectively (1). Imatinib and dasatinib have similar inhibitory mechanisms, but dasatinib displays greater potency in imatinib-resistant cell lines and greater inhibitory effect on platelet derived growth factor (PDGF) (2,3).
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.